Canterbury DHB

Context

Further Reading

  1. Maffioli M, et al. (2017). Polycythemia Vera: From New, Modified Diagnostic Criteria to New Therapeutic Approaches. Clinical Advances in Hematology & Oncology Volume 15, Issue 9 September 2017.
  2. Cazzola M (2016). Introduction to a review series: the 2016 revision of the WHO classification of tumors of hematopoietic and lymphoid tissues Blood 2016 127:2361-2364; doi: https://doi.org/10.1182.
  3. Thiele J, et al. (2005). Bone Marrow Histopathology in Myeloproliferative Disorders—Current Diagnostic Approach. Semin Hematol 42(4): 184-95.
  4. McMullin MF, et al. (2013). Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. British Journal of Haematology. Vol 130, issue 2. https://doi.org/10.1111.
  5. Perloff JK, et al. (1993). Risk of stroke in adults with cyanotic congenital heart disease. Circulation 87(6): 1954-1959.
  6. Tefferi A, et al (2018). Polycythaemia vera treatment algorithm 2018. Journal of Blood Cancer, article 3.
  7. Barbui T, et al. (2011). Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. Journal of Clinical Oncology 29(6): 761-770.
  8. Kiladjian JJ, et al. (2008). Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood.112(8):3065.
  9. Verstovsek S (2016). Myeloproliferative Neoplasms. Cancer Network
  10. Alvarez-Larran A, et al. (2012). Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera. Blood 119(6): 1363-1369.
  11. Finazzi G, et al. (2005). Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood. 105(7):2664.
  12. Landolfi R, et al. (2004). Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med.;350(2):114.
  13. Passamonti F. (2012). How I treat polycythemia vera. Blood 120(2): 275-284.
  14. Samuelsson J, et al. (2006). A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life. Blood Cancer. 2006;106(11):2397.
  15. Sever M, et al. (2014). Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea. Leukemia & Lymphoma 0(0): 1-6.
  16. Tefferi A, et al. (2014). Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. Oct;124(16):2507-13.
  17. Tefferi A (2013). Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol 88(6): 507-516.

About this Canterbury DHB document (536151):

Document Owner:

Andrew Butler (see Who's Who)

Issue Date:

August 2018

Next Review:

April 2021

Keywords:

Note: Only the electronic version is controlled. Once printed, this is no longer a controlled document. Disclaimer

Topic Code: 536151